Immunotherapy in Prostate Cancer: From a “Cold” Tumor to a “Hot” Prospect
Cancers · 21.03.2025 · 17 (7) · 1064
DOI: 10.3390/cancers17071064 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 21.03.2025. Verfasst von Whi-An Kwon und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Hanyang University College of Medicine, Myongji Hospital, Goyang 10475, Republic of Korea. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 128 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Cancer Center.
Abstract (Originalsprache)
Immunotherapy has shown limited efficacy in prostate cancer, largely due to low tumor immunogenicity, sparse tumor-infiltrating lymphocytes, and a suppressive microenvironment. Recent therapeutic strategies aim to boost immune responses and counteract immunosuppressive factors through interventions such as immune checkpoint inhibitors, immunogenic cell death-inducing therapies, and the targeted blockade of pathways like that of transforming growth factor-β. Vaccine-based approaches, potent immune adjuvants, and engineered chimeric antigen receptor (CAR) T cells are also being investigated to overcome local immune inhibitory signals. Advancements in imaging, multi-omic profiling, and liquid biopsies offer promising avenues for real-time monitoring, better patient selection, and precision treatment. This review provides an overview of the key immunosuppressive features of prostate cancer, current immunotherapeutic modalities, and emerging strategies to transform “cold” tumors into more responsive “hot” targets. By integrating these approaches, we may achieve more durable clinical benefits for patients with advanced or metastatic prostate cancer.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Hanyang University College of Medicine, Myongji Hospital, Goyang 10475, Republic of Korea.
- Department of Urology, Urological Cancer Center, National Cancer Center, Goyang 10408, Republic of Korea.
ORCID-Profile: Whi-An Kwon
Förderung
- National Cancer Center
Zitieren
APA
Kwon, W. A., & Joung, J. Y. (2025). Immunotherapy in Prostate Cancer: From a “Cold” Tumor to a “Hot” Prospect. Cancers, 17(7), 1064. https://doi.org/10.3390/cancers17071064
Vancouver
Kwon WA, Joung JY. Immunotherapy in Prostate Cancer: From a “Cold” Tumor to a “Hot” Prospect. Cancers. 2025;17(7):1064. doi:10.3390/cancers17071064
BibTeX
@article{Kwon2025,
author = {Kwon, Whi-An and Joung, Jae Young},
title = {Immunotherapy in Prostate Cancer: From a “Cold” Tumor to a “Hot” Prospect},
journal = {Cancers},
year = {2025},
volume = {17},
number = {7},
pages = {1064},
doi = {10.3390/cancers17071064}
}
EUVIMED